Co-Diagnostics, Inc. (CODX): Nasdaq/NYSE listing notice — Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14

Co-Diagnostics, Inc.

Nasdaq Staff determined to delist CODX due to continued non-compliance with minimum bid price rule.
Trading on Nasdaq suspended from open on Jan 14, 2026; shares expected to trade on OTC Pink under CODX.
Company plans to request a hearing with Nasdaq Hearings Panel to address bid price deficiency.
Since Jan 2, 2026 (1-for-30 reverse split effective), bid price closed at or above $1.00; may seek compliance if 10 consecutive days ending Jan 15 show $1.00.
Prior non-compliance notice Jan 10, 2025; two compliance periods expired Jan 5, 2026 without meeting rule.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Co-Diagnostics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5815(a)(1)(B)(ii)(d)

Exact text from the filing

January 7, 2026, Co-Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market due to the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company plans to timely request a hearing before the Nasdaq Hearings Panel to address the bid price deficiency; however, the Company’s securi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-001971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.